Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tonkin

Showing results (21-30 of 163) with videos related to

Pageof 17
Sort By:
American Heart Journal|April 8, 2003
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague, Peta Forder, John Simes, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|September 10, 2009
Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 14, 2003
Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart diseaseBruce Neal, Stephen MacMahon, Takayoshi Ohkubo, et al.
Australian Family Physician|July 7, 2005
Chronic heart failure--optimising care in general practiceLeon Piterman, Hendrik Zimmet, Henry Krum, et al.
European Heart Journal|October 25, 2002
Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart diseaseBruce Neal, Stephen MacMahon, Takayoshi Ohkubo, et al.
Journal of Cardiac Failure|April 22, 2014
Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysisIngrid Hopper, Rohit Samuel, Christopher Hayward, et al.
International Journal of Cardiology|January 29, 2019
The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspectiveElla Zomer, Danny Liew, Andrew Tonkin, et al.
Journal of Cardiac Failure|May 25, 2016
Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart FailureIngrid Hopper, Carolyn de Silva, Marina Skiba, et al.
International Journal of Cardiology|February 4, 2016
Polypharmacy in heart failure - Is reducing medication safe?Ingrid Hopper, Marina Skiba, Emma Windebank, et al.
Plos One|January 25, 2020
Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort studyMelita J Giummarra, Hilarie Tardif, Megan Blanchard, et al.
Pageof 17

Showing results (21-30 of 163) with videos related to

Sort By:
Pageof 17
American Heart Journal|April 8, 2003
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague, Peta Forder, John Simes, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|September 10, 2009
Laboratory and non-laboratory-based risk prediction models for secondary prevention of cardiovascular disease: the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 14, 2003
Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart diseaseBruce Neal, Stephen MacMahon, Takayoshi Ohkubo, et al.
Australian Family Physician|July 7, 2005
Chronic heart failure--optimising care in general practiceLeon Piterman, Hendrik Zimmet, Henry Krum, et al.
European Heart Journal|October 25, 2002
Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart diseaseBruce Neal, Stephen MacMahon, Takayoshi Ohkubo, et al.
Journal of Cardiac Failure|April 22, 2014
Can medications be safely withdrawn in patients with stable chronic heart failure? systematic review and meta-analysisIngrid Hopper, Rohit Samuel, Christopher Hayward, et al.
International Journal of Cardiology|January 29, 2019
The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspectiveElla Zomer, Danny Liew, Andrew Tonkin, et al.
Journal of Cardiac Failure|May 25, 2016
Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart FailureIngrid Hopper, Carolyn de Silva, Marina Skiba, et al.
International Journal of Cardiology|February 4, 2016
Polypharmacy in heart failure - Is reducing medication safe?Ingrid Hopper, Marina Skiba, Emma Windebank, et al.
Plos One|January 25, 2020
Hypertension prevalence in patients attending tertiary pain management services, a registry-based Australian cohort studyMelita J Giummarra, Hilarie Tardif, Megan Blanchard, et al.
Pageof 17